Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Glucagon-like Peptide-1 receptor-based therapeutics for metabolic liver disease
Treatment depends on the underlying cause and may include surgery for pituitary or adrenal tumours, specific medications for Cushing's syndrome, or glucocorticoid replacement therapy for adrenal insufficiency
The climbing demand for these drugs driven by expanded indications and increasing off-label use for cosmetic weight loss, led to insurmountable shortages on the market
This combination can lead to increased muscle mass, reduced body fat, enhanced metabolism, improved overall body composition, and improved physiological function
The injectable version demonstrated an average weight loss of 14.9% over 68 weeks in the STEP 1 trial, underscoring its effectiveness when combined with dietary and lifestyle changes
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
